PMID- 12949432
OWN - NLM
STAT- MEDLINE
DCOM- 20040211
LR  - 20181130
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 68
IP  - 1
DP  - 2003
TI  - Response to combination therapy with interferon alfa-2a and ribavirin in chronic 
      hepatitis C according to a TNF-alpha promoter polymorphism.
PG  - 1-4
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is involved in the 
      pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region 
      of the TNF-alpha gene can alter the TNF-alpha expression and modify the host 
      immune response. The present study aimed at the correlation of the G308A 
      TNF-alpha polymorphism with the response to antiviral combination therapy in 
      chronic hepatitis C. PATIENTS AND METHODS: 62 patients with HCV and 119 healthy 
      unrelated controls were genotyped for the G308A TNF-alpha promoter polymorphism. 
      The patients received 3 x 3 million units of interferon alfa-2a and 1,000-1,200 
      mg ribavirin daily according to their body weight. A response was defined as 
      absence of HCV-RNA and normalization of S-ALT after 6 months of combination 
      therapy. RESULTS: With respect to the allele and genotype frequency, a 
      significant difference was not observed between controls and patients with 
      chronic hepatitis C. Furthermore, such a difference was also not observed if 
      responders and non-responders to antiviral therapy were compared. CONCLUSIONS: 
      The promoter polymorphism of the TNF-alpha gene investigated herein is equally 
      distributed in healthy individuals and patients with hepatitis C and does not 
      seem to predict the response to therapy with interferon alfa-2a and ribavirin.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Schiemann, U
AU  - Schiemann U
AD  - Medizinische Klinik, Klinikum der Universitat, Innenstadt, 
      Ludwig-Maximilians-Universitat Munchen, Munchen, Deutschland. 
      usciema@helios.med.uni-muenchen.de
FAU - Glas, J
AU  - Glas J
FAU - Torok, P
AU  - Torok P
FAU - Simperl, C
AU  - Simperl C
FAU - Martin, K
AU  - Martin K
FAU - Konig, A
AU  - Konig A
FAU - Schmidt, F
AU  - Schmidt F
FAU - Schaefer, M
AU  - Schaefer M
FAU - Folwaczny, C
AU  - Folwaczny C
LA  - eng
PT  - Journal Article
DEP - 20030829
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Antiviral Agents/*therapeutic use
MH  - Case-Control Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Polymorphism, Genetic
MH  - *Promoter Regions, Genetic
MH  - Recombinant Proteins
MH  - Ribavirin/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/*genetics
EDAT- 2003/09/02 05:00
MHDA- 2004/02/12 05:00
CRDT- 2003/09/02 05:00
PHST- 2003/02/28 00:00 [received]
PHST- 2003/05/22 00:00 [accepted]
PHST- 2003/09/02 05:00 [pubmed]
PHST- 2004/02/12 05:00 [medline]
PHST- 2003/09/02 05:00 [entrez]
AID - 73218 [pii]
AID - 10.1159/000073218 [doi]
PST - ppublish
SO  - Digestion. 2003;68(1):1-4. doi: 10.1159/000073218. Epub 2003 Aug 29.